EDIT - Editas sickle cell candidate granted FDA Orphan Drug designation
2023-04-27 09:24:19 ET
- The US FDA has granted Orphan Drug status to EDIT-301, Editas Medicines' ( NASDAQ: EDIT ) gene editing therapy for sickle cell disease.
- The treatment already had the status for beta thalassemia.
- EDIT-301 also has Rare Pediatric Disease designation for beta thalassemia and sickle cell disease.
- Seeking Alpha's Quant Rating views Editas ( EDIT ) as a hold.
For further details see:
Editas sickle cell candidate granted FDA Orphan Drug designation